DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Lindsay M. Morton, Sophia S. Wang, Andrew W. Bergen, Nilanjan Chatterjee, Paul Kvale, Robert Welch, Meredith Yeager, Richard B. Hayes, Stephen J. Chanock, Neil E. Caporaso

Research output: Contribution to journalArticle

Abstract

OBJECTIVES: Cigarette smoking is the leading cause of morbidity and mortality worldwide. We investigated the association between smoking behavior and genetic variations in the D2 dopamine receptor (DRD2), which mediates nicotine dependence. To assess the specificity of genetic effects, we also investigated other reward-motivated characteristics (obesity, alcohol consumption). METHODS: Four single nucleotide polymorphisms in DRD2 were genotyped in 2374 participants selected randomly from the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial after stratifying by sex, age, and smoking status. Smoking, obesity, and alcohol consumption were assessed by questionnaire. Single nucleotide polymorphism and haplotype associations were estimated using odds ratios (ORs) and 95% confidence intervals derived from conditional logistic regression models, adjusted for race/ethnicity. RESULTS: DRD2 polymorphisms were associated with the risk of remaining a current smoker and obesity. Current smokers were more likely than former smokers to possess the variant TaqIA allele (rs#1800497) in a dose-dependent model (ORCT=1.2, ORTT=1.5, P for linear trend=0.007). The DRD2 haplotype T-C-T-A [TaqIA(C/T)-957(T/C)-IVS6-83(G/T)- -50977(A/G)] was more common among current than former smokers (OR=1.3, P=0.006), particularly among heavy smokers (21+ cigarettes per day; OR=1.6, P=0.006), and was more common among obese than normal weight individuals (OR=1.4, P=0.02). CONCLUSIONS: Genetic variation in DRD2 is a modifier of the reward-motivated characteristics, smoking and obesity. As fewer than 15% of smokers who attempt to quit are able to maintain abstinence for greater than 3 months, our results support that DRD2 is an appropriate molecular target for smoking cessation treatments. Our results further support evaluation of DRD2 antagonists for obesity therapies.

Original languageEnglish (US)
Pages (from-to)901-910
Number of pages10
JournalPharmacogenetics and Genomics
Volume16
Issue number12
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Early Detection of Cancer
Ovarian Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Obesity
Smoking
Odds Ratio
Reward
Alcohol Drinking
Haplotypes
Single Nucleotide Polymorphism
Logistic Models
Tobacco Use Disorder
Withholding Treatment
Dopamine D2 Receptors
Smoking Cessation
Tobacco Products
Alleles
Confidence Intervals

Keywords

  • Alcohol consumption
  • Dopamine
  • Obesity
  • Smoking
  • Smoking cessation

ASJC Scopus subject areas

  • Genetics
  • Pharmacology

Cite this

DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. / Morton, Lindsay M.; Wang, Sophia S.; Bergen, Andrew W.; Chatterjee, Nilanjan; Kvale, Paul; Welch, Robert; Yeager, Meredith; Hayes, Richard B.; Chanock, Stephen J.; Caporaso, Neil E.

In: Pharmacogenetics and Genomics, Vol. 16, No. 12, 12.2006, p. 901-910.

Research output: Contribution to journalArticle

Morton, Lindsay M. ; Wang, Sophia S. ; Bergen, Andrew W. ; Chatterjee, Nilanjan ; Kvale, Paul ; Welch, Robert ; Yeager, Meredith ; Hayes, Richard B. ; Chanock, Stephen J. ; Caporaso, Neil E. / DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. In: Pharmacogenetics and Genomics. 2006 ; Vol. 16, No. 12. pp. 901-910.
@article{a99fb8bc81da411f988135d18d30d190,
title = "DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial",
abstract = "OBJECTIVES: Cigarette smoking is the leading cause of morbidity and mortality worldwide. We investigated the association between smoking behavior and genetic variations in the D2 dopamine receptor (DRD2), which mediates nicotine dependence. To assess the specificity of genetic effects, we also investigated other reward-motivated characteristics (obesity, alcohol consumption). METHODS: Four single nucleotide polymorphisms in DRD2 were genotyped in 2374 participants selected randomly from the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial after stratifying by sex, age, and smoking status. Smoking, obesity, and alcohol consumption were assessed by questionnaire. Single nucleotide polymorphism and haplotype associations were estimated using odds ratios (ORs) and 95{\%} confidence intervals derived from conditional logistic regression models, adjusted for race/ethnicity. RESULTS: DRD2 polymorphisms were associated with the risk of remaining a current smoker and obesity. Current smokers were more likely than former smokers to possess the variant TaqIA allele (rs#1800497) in a dose-dependent model (ORCT=1.2, ORTT=1.5, P for linear trend=0.007). The DRD2 haplotype T-C-T-A [TaqIA(C/T)-957(T/C)-IVS6-83(G/T)- -50977(A/G)] was more common among current than former smokers (OR=1.3, P=0.006), particularly among heavy smokers (21+ cigarettes per day; OR=1.6, P=0.006), and was more common among obese than normal weight individuals (OR=1.4, P=0.02). CONCLUSIONS: Genetic variation in DRD2 is a modifier of the reward-motivated characteristics, smoking and obesity. As fewer than 15{\%} of smokers who attempt to quit are able to maintain abstinence for greater than 3 months, our results support that DRD2 is an appropriate molecular target for smoking cessation treatments. Our results further support evaluation of DRD2 antagonists for obesity therapies.",
keywords = "Alcohol consumption, Dopamine, Obesity, Smoking, Smoking cessation",
author = "Morton, {Lindsay M.} and Wang, {Sophia S.} and Bergen, {Andrew W.} and Nilanjan Chatterjee and Paul Kvale and Robert Welch and Meredith Yeager and Hayes, {Richard B.} and Chanock, {Stephen J.} and Caporaso, {Neil E.}",
year = "2006",
month = "12",
doi = "10.1097/01.fpc.0000230417.20468.d0",
language = "English (US)",
volume = "16",
pages = "901--910",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

AU - Morton, Lindsay M.

AU - Wang, Sophia S.

AU - Bergen, Andrew W.

AU - Chatterjee, Nilanjan

AU - Kvale, Paul

AU - Welch, Robert

AU - Yeager, Meredith

AU - Hayes, Richard B.

AU - Chanock, Stephen J.

AU - Caporaso, Neil E.

PY - 2006/12

Y1 - 2006/12

N2 - OBJECTIVES: Cigarette smoking is the leading cause of morbidity and mortality worldwide. We investigated the association between smoking behavior and genetic variations in the D2 dopamine receptor (DRD2), which mediates nicotine dependence. To assess the specificity of genetic effects, we also investigated other reward-motivated characteristics (obesity, alcohol consumption). METHODS: Four single nucleotide polymorphisms in DRD2 were genotyped in 2374 participants selected randomly from the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial after stratifying by sex, age, and smoking status. Smoking, obesity, and alcohol consumption were assessed by questionnaire. Single nucleotide polymorphism and haplotype associations were estimated using odds ratios (ORs) and 95% confidence intervals derived from conditional logistic regression models, adjusted for race/ethnicity. RESULTS: DRD2 polymorphisms were associated with the risk of remaining a current smoker and obesity. Current smokers were more likely than former smokers to possess the variant TaqIA allele (rs#1800497) in a dose-dependent model (ORCT=1.2, ORTT=1.5, P for linear trend=0.007). The DRD2 haplotype T-C-T-A [TaqIA(C/T)-957(T/C)-IVS6-83(G/T)- -50977(A/G)] was more common among current than former smokers (OR=1.3, P=0.006), particularly among heavy smokers (21+ cigarettes per day; OR=1.6, P=0.006), and was more common among obese than normal weight individuals (OR=1.4, P=0.02). CONCLUSIONS: Genetic variation in DRD2 is a modifier of the reward-motivated characteristics, smoking and obesity. As fewer than 15% of smokers who attempt to quit are able to maintain abstinence for greater than 3 months, our results support that DRD2 is an appropriate molecular target for smoking cessation treatments. Our results further support evaluation of DRD2 antagonists for obesity therapies.

AB - OBJECTIVES: Cigarette smoking is the leading cause of morbidity and mortality worldwide. We investigated the association between smoking behavior and genetic variations in the D2 dopamine receptor (DRD2), which mediates nicotine dependence. To assess the specificity of genetic effects, we also investigated other reward-motivated characteristics (obesity, alcohol consumption). METHODS: Four single nucleotide polymorphisms in DRD2 were genotyped in 2374 participants selected randomly from the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial after stratifying by sex, age, and smoking status. Smoking, obesity, and alcohol consumption were assessed by questionnaire. Single nucleotide polymorphism and haplotype associations were estimated using odds ratios (ORs) and 95% confidence intervals derived from conditional logistic regression models, adjusted for race/ethnicity. RESULTS: DRD2 polymorphisms were associated with the risk of remaining a current smoker and obesity. Current smokers were more likely than former smokers to possess the variant TaqIA allele (rs#1800497) in a dose-dependent model (ORCT=1.2, ORTT=1.5, P for linear trend=0.007). The DRD2 haplotype T-C-T-A [TaqIA(C/T)-957(T/C)-IVS6-83(G/T)- -50977(A/G)] was more common among current than former smokers (OR=1.3, P=0.006), particularly among heavy smokers (21+ cigarettes per day; OR=1.6, P=0.006), and was more common among obese than normal weight individuals (OR=1.4, P=0.02). CONCLUSIONS: Genetic variation in DRD2 is a modifier of the reward-motivated characteristics, smoking and obesity. As fewer than 15% of smokers who attempt to quit are able to maintain abstinence for greater than 3 months, our results support that DRD2 is an appropriate molecular target for smoking cessation treatments. Our results further support evaluation of DRD2 antagonists for obesity therapies.

KW - Alcohol consumption

KW - Dopamine

KW - Obesity

KW - Smoking

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=33751105517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751105517&partnerID=8YFLogxK

U2 - 10.1097/01.fpc.0000230417.20468.d0

DO - 10.1097/01.fpc.0000230417.20468.d0

M3 - Article

VL - 16

SP - 901

EP - 910

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 12

ER -